News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.


Posted on: 06/20/2007

J Neurooncol. 2007 Jun 19; [Epub ahead of print] Related Articles


Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A.

Department of Neuro-oncology, Fondazione IRCCS Istituto Neurologico " Carlo Besta", Via Celoria, 11, Milan, 20133, Italy, silvani@istituto-besta.it.

The purpose of this study was to evaluate safety and efficacy of Procarbazine (PCB) and fotemustine (FTM) combination in the treatment of pre-temozolomide treated, recurrent GBM patients\. The primary end-point was progression free survival at 6 months (PFS-6)\. Secondary end-points were overall survival, response rates (CR + PR) and toxicity\. About 54 patients (41 men and 13 women) aged 26-68 years (median age, 53.5 years) with recurrent GBM were treated\. PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3\. FTM was administered on day 3, 3 h after the last PCB intake at a dose of 110 mg/mq/BSA\. The treatment was repeated every 5 weeks\. Treatment was continued for a maximum of six cycles or until disease progression\. After two cycles of chemotherapy: 6 patients (11.2%) experienced a neuroradiographic partial response (PR), 29 patients (53.7%) had stable disease (SD), and 19 patients (35.1%) had progressive disease (PD)\. For the whole group of patients, the median PFS was 19.3 weeks (95% CI, 14.1-24.4 weeks), and PFS-6 was 26.7% (95% CI, 10.6-42.8%)\. Overall MST from the beginning of PCB + FTM chemotherapy was 28.7 weeks (95% CI, 24.8-32.7 weeks)\. At 6 and 12 months, 64.4% (95% CI, 51.5-77.3%) and 23.6% (95% CI, 10.1-37.1%) of patients were alive\. The median survival time calculated from the first diagnosis was 20.8 months (95% CI, 16.7-24.8)\. We concluded that the PCB + FTM combination as done in the current trial for patients with recurrent GBM after treatment with TMZ showed some benefit with regards to increased survival and that a Phase III trial is warranted.

PMID: 17576523 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740